BR0211173A - Formulação galênica injetável para utilização em um diagnóstico ou em uma terapia fotodinâmica e processo de preparação da mesma - Google Patents

Formulação galênica injetável para utilização em um diagnóstico ou em uma terapia fotodinâmica e processo de preparação da mesma

Info

Publication number
BR0211173A
BR0211173A BR0211173-0A BR0211173A BR0211173A BR 0211173 A BR0211173 A BR 0211173A BR 0211173 A BR0211173 A BR 0211173A BR 0211173 A BR0211173 A BR 0211173A
Authority
BR
Brazil
Prior art keywords
diagnosis
preparation process
photodynamic therapy
formulation
galenic formulation
Prior art date
Application number
BR0211173-0A
Other languages
English (en)
Inventor
Pierre-Herve Brun
Alain Prudhomme
Jean-Luc Barnoux
Original Assignee
Steba Biotech N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steba Biotech N V filed Critical Steba Biotech N V
Publication of BR0211173A publication Critical patent/BR0211173A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"FORMULAçãO GALêNICA INJETáVEL PARA UTILIZAçãO EM UM DIAGNóSTICO OU EM UMA TERAPIA FOTODINâMICA E PROCESSO DE PREPARAçãO DA MESMA". Descreve-se uma formulação galênica injetável para a utilização em um diagnóstico ou em uma terapia fotodinâmica (PDT) e o seu processo de preparação. A formulação contém: um composto representado pela fórmula geral (I) a seguir: na qual R~ 2~ representa um grupo H, OH ou COOR~ 4~, em que R~ 4~ é um hidrogênio ou um alquila em C~ 1~-C~ 12~ ou um cicloalquila em C~ 3~-C~ 12~, R~ 3~ representa H, OH ou um alquila ou alcóxi em C~ 1~C~ 12~ e * representa um carbono assimétrico sob a forma de um sal de metal alcalino, em uma quantidade que não ultrapassa 10 mg/ml, como agente fotossensibilizador e um veículo em fase aquosa que contém pelo menos uma mistura de álcool benzílico - etanol ou propileno glicol como agente de solubilização do agente fotossensibilizador e um tensoativo em uma quantidade que não ultrapassa 20% em peso em relação ao peso total da formulação.
BR0211173-0A 2001-07-17 2002-07-05 Formulação galênica injetável para utilização em um diagnóstico ou em uma terapia fotodinâmica e processo de preparação da mesma BR0211173A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01810708A EP1277470A1 (fr) 2001-07-17 2001-07-17 Formulation galénique injectable pour utilisation dans un diagnostic ou une thérapie photodynamique et son procédé de préparation
PCT/IB2002/002661 WO2003009842A1 (fr) 2001-07-17 2002-07-05 Formulation galenique injectable pour utilisation dan un diagnostic ou une therapie photodynamique et son procede de preparation

Publications (1)

Publication Number Publication Date
BR0211173A true BR0211173A (pt) 2004-08-10

Family

ID=8184036

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211173-0A BR0211173A (pt) 2001-07-17 2002-07-05 Formulação galênica injetável para utilização em um diagnóstico ou em uma terapia fotodinâmica e processo de preparação da mesma

Country Status (20)

Country Link
US (1) US20040147500A1 (pt)
EP (2) EP1277470A1 (pt)
JP (1) JP2004537562A (pt)
CN (1) CN1303999C (pt)
AT (1) ATE372769T1 (pt)
BR (1) BR0211173A (pt)
CA (1) CA2454150A1 (pt)
DE (1) DE60222421T2 (pt)
DK (1) DK1406616T3 (pt)
ES (1) ES2292781T3 (pt)
HU (1) HUP0400754A3 (pt)
IL (1) IL159620A0 (pt)
MX (1) MXPA04000042A (pt)
NO (1) NO20040216L (pt)
NZ (1) NZ530634A (pt)
PL (1) PL368503A1 (pt)
PT (1) PT1406616E (pt)
RU (1) RU2278665C2 (pt)
WO (1) WO2003009842A1 (pt)
ZA (1) ZA200400328B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825153B2 (en) * 2004-08-16 2010-11-02 Ceramoptec Industries, Inc. Photosensitizer formulations and their use
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
EP2008665A1 (fr) * 2007-06-25 2008-12-31 Steba Biotech N.V. Formulation injectable pour thérapie photodynamique
RU2565766C1 (ru) * 2014-11-17 2015-10-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Л. Гольдберга" 4-(3,4-дибромтиофенкарбонил)-2,6,8,12-тетраацетил-2,4,6,8,10,12-гексаазатетрацикло[5,5,0,03,11,05,9]додекан в качестве анальгетического средства и способ его получения
PL3225112T3 (pl) * 2016-04-01 2022-01-03 Trioptotec Gmbh Dyspersja fotouczulacza i jej zastosowanie
CN108670950B (zh) * 2018-06-29 2020-10-02 深圳海王医药科技研究院有限公司 一种不含有机溶剂的虎杖苷药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2963178B2 (ja) * 1990-09-27 1999-10-12 株式会社エス・エル・ティ・ジャパン 水溶性フェオホーバイドａの製造方法
US5654423A (en) * 1990-11-21 1997-08-05 Regents Of The University Of California Boronated metalloporphyrine and therapeutic methods
WO1994014956A1 (en) * 1992-12-23 1994-07-07 Iowa State University Research Foundation, Inc. Molecular flashlight
US6147195A (en) * 1993-07-26 2000-11-14 Yeda Research And Development Co., Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5616342A (en) * 1995-04-11 1997-04-01 Pdt, Inc. Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
IL116126A0 (en) * 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
PT1137411E (pt) * 1998-12-09 2007-02-28 Yeda Res & Dev Processo para inibir respostas ao etileno em plantas

Also Published As

Publication number Publication date
DK1406616T3 (da) 2008-01-21
ZA200400328B (en) 2004-09-13
DE60222421D1 (de) 2007-10-25
WO2003009842A1 (fr) 2003-02-06
EP1406616B1 (fr) 2007-09-12
EP1406616A1 (fr) 2004-04-14
CN1529594A (zh) 2004-09-15
JP2004537562A (ja) 2004-12-16
DE60222421T2 (de) 2008-06-05
IL159620A0 (en) 2004-06-01
NO20040216L (no) 2004-03-17
CA2454150A1 (fr) 2003-02-06
HUP0400754A3 (en) 2005-11-28
EP1277470A1 (fr) 2003-01-22
NZ530634A (en) 2006-11-30
RU2278665C2 (ru) 2006-06-27
PL368503A1 (en) 2005-04-04
RU2004104469A (ru) 2005-04-20
MXPA04000042A (es) 2005-08-16
ATE372769T1 (de) 2007-09-15
US20040147500A1 (en) 2004-07-29
HUP0400754A2 (hu) 2004-07-28
WO2003009842A8 (fr) 2004-04-01
ES2292781T3 (es) 2008-03-16
PT1406616E (pt) 2007-12-20
CN1303999C (zh) 2007-03-14

Similar Documents

Publication Publication Date Title
BRPI0511036A (pt) formulações de solução farmacêuticas contendo 17-aag
KR890000098A (ko) 세포 및 조직 수복제
AR011846A1 (es) Una composicion farmaceutica, y el procedimiento para prepararla
CO5050325A1 (es) Composiciones que contienen acidos difosfonicos
US5219880A (en) Treatment of viral tumors and hemorrhoids with artemisinin and derivatives
BR0211173A (pt) Formulação galênica injetável para utilização em um diagnóstico ou em uma terapia fotodinâmica e processo de preparação da mesma
DE69231298T2 (de) Substituierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen und Anwendungsmethoden
US6127351A (en) Method for the administration of amifostine and related compounds
US20030125388A1 (en) 5-Aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
ATE156119T1 (de) 2-formylpyridin-thiosemicarbazonderivate, ihre herstellung und ihre verwendung als antitumor mittel
BR9916845A (pt) Compostos de (aminoiminometil ouaminometil)benzo-heteroarila substituìdos
BRPI0409413A (pt) composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável
KR960007538A (ko) 알킬벤조일구아니딘 유도체
BR9811843A (pt) Sistema de agente de consevação para produtos de tratamento corporal
HUP9801712A2 (hu) Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása
GB2094142A (en) Injectable solution containing theophylline and a basic amino acid
KR880002518A (ko) 소염제 조성물
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi
IL105947A0 (en) Preparation for topical use,having light protection properties
PE20030092A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
BR9917315A (pt) Composições medicinais para liberação imediata para uso oral
DK166754B1 (da) Stabilt, injicerbart praeparat indeholdende 1,4-dihydroxy-5,8-bis-oe2-(2-hydroxyethylamino)-ethylaminoaa-anthraquinon, dihydrochlorid
BR0208412A (pt) Agente terapêutico para a hipersensibilidade da bexiga, uso de um composto tricìclico ou de seu sal farmaceuticamente aceitável, e, método para tratar a hipersensibilidade da bexiga
BR0202419A (pt) Compostos de 3-fenil-3,7-diazabiciclo[3,3,1]nonano, bem como processo para a sua preparação e medicamento contendo estes compostos
BR0208416A (pt) Agente teraupêutico para os sintomas irritativos da bexiga associados com a hiperplasia prostática benigna, uso do composto tricìclico ou de seu sal farmaceuticamente aceitável, e, método para tratar os sintomas irritativos da bexiga associados com a hiperplasia prostática benigna

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A A NUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.